Elevated expression of TUBA1C in breast cancer predicts poor prognosis
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0263710 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Yi Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research & Development and Transformation Project of Qinghai Province for 2018.
Abstract (Originalsprache)
α1C-tubulin ( TUBA1C ) is a member of the α-tubulin family and has served as a potential biomarker in a variety of cancers in many studies. In this study, the gene expression profile of TUBA1C in The Cancer Genome Atlas (TCGA) was extracted for analysis, and the prognostic value of TUBA1C in breast cancer was comprehensively evaluated. The Wilcoxon signed-rank test, Kruskal-Wallis test, and logistic regression analysis were performed to confirm the correlations between TUBA1C expression and the clinical characteristics of breast cancer patients. The effect of TUBA1C expression on the survival of breast cancer patients was assessed by Kaplan-Meier curve, Cox regression analysis, and the Kaplan-Meier plotter (an online database). The TCGA data set was used for the Gene Set Enrichment Analysis (GSEA). The results confirmed that high TUBA1C expression in breast cancer was closely correlated with survival time, survival status, and tumor size. In addition, elevated TUBA1C expression can predict poor overall survival (OS), recurrence-free survival (RFS), and distant metastasis-free survival (DMFS). Univariate and multivariate analyses (Cox regression analyses) confirmed that TUBA1C was an independent prognostic factor for the OS of breast cancer patients. The GSEA identified that the high TUBA1C expression phenotype was differentially enriched in cell cycle, basal transcription factor, P53 signaling pathway, pathways in cancer, TOLL-like receptor signaling pathway, and NOD-like receptor signaling pathway. In summary, high messenger RNA (mRNA) expression of TUBA1C is an independent risk factor for poor prognosis of breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, QingHai, China.
- Department of Pharmacogenomics, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an, Shaanxi, China.
- Graduate School of Qinghai University, Xining, QingHai, China.
ORCID-Profile: Yi Zhao
Förderung
- Key Research & Development and Transformation Project of Qinghai Province for 2018
Zitieren
APA
Zhao, Y., Wang, W., Li, J., Du, J., Xie, Q., Wang, M., Liu, Z., Huo, X., Zhao, F., Ren, D., Zhao, J., & Shen, G. (2023). Elevated expression of TUBA1C in breast cancer predicts poor prognosis. PLOS ONE. https://doi.org/10.1371/journal.pone.0263710
Vancouver
Zhao Y, Wang W, Li J, Du J, Xie Q, Wang M, et al. Elevated expression of TUBA1C in breast cancer predicts poor prognosis. PLOS ONE. 2023. doi:10.1371/journal.pone.0263710
BibTeX
@article{Zhao2023,
author = {Zhao, Yi and Wang, Wenwen and Li, Jinming and Du, Jiarui and Xie, Qiqi and Wang, Miaozhou and Liu, Zhen and Huo, Xingfa and Zhao, Fuxing and Ren, Dengfeng and Zhao, Jiuda and Shen, GuoShuang},
title = {Elevated expression of TUBA1C in breast cancer predicts poor prognosis},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0263710}
}
EUVIMED